SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection

SARS-CoV-2疫苗诱导产生的抗体可预防奥密克戎病毒突破性感染

阅读:7
作者:Eva A M Baerends ,Astrid K Hvidt ,Joanne Reekie ,Ole S Søgaard ,Nina B Stærke ,Dorthe Raben ,Henrik Nielsen ,Kristine T Petersen ,Maria R Juhl ,Isik S Johansen ,Susan O Lindvig ,Lone W Madsen ,Lothar Wiese ,Lene S Knudsen ,Mette B Iversen ,Thomas Benfield ,Kasper K Iversen ,Sidsel D Andersen ,Anna K Juhl ,Lisa L Dietz ,Signe R Andreasen ,Thea K Fischer ,Christian Erikstrup ,Palle Valentiner-Branth ,Jens Lundgren ,Lars Østergaard ,Martin Tolstrup

Abstract

SARS-CoV-2 Omicron quickly spread globally, also in regions with high vaccination coverage, emphasizing the importance of exploring the immunological requirements for protection against Omicron breakthrough infection. The test-negative matched case-control study (N = 964) characterized Omicron breakthrough infections in triple-vaccinated individuals from the ENFORCE cohort. Within 60 days before a PCR test spike-specific IgG levels were significantly lower in cases compared to controls (GMR [95% CI] for BA.2: 0.83 [0.73-0.95], p = 0.006). Multivariable logistic regression showed significant associations between high antibody levels and lower odds of infection (aOR [95% CI] for BA.2 spike-specific IgG: 0.65 [0.48-0.88], p = 0.006 and BA.2 ACE2-blocking antibodies: 0.46 [0.30-0.69], p = 0.0002). A sex-stratified analysis showed more pronounced associations for females than males. High levels of vaccine-induced antibodies provide partial protection against Omicron breakthrough infections. This is important knowledge to further characterize a threshold for protection against new variants and to estimate the necessity and timing of booster vaccination.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。